{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"Incidence of acute Graft versus host disease (GVHD) grades II-IV (before day 60 T cell add back)\n\nModified \"Glucksberg\" grading","groups":[{"description":"Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. CD34 selection and T cell depletion using Isolex 300i immuno-magnetic cell selection and immunosuppression during peri- transplant.","id":"OG000","title":"Bone Marrow Transplantation Using \"Nexell Isolex 300i\""}],"paramType":"NUMBER","populationDescription":"Per protocol","reportingStatus":"POSTED","timeFrame":"First 60 days","title":"Acute Graft Versus Host Disease (Before Day 60 T Cell Add Back)","type":"SECONDARY","unitOfMeasure":"participants"}